Literature DB >> 2829215

Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle.

M M Heck1, W N Hittelman, W C Earnshaw.   

Abstract

We have utilized antibody probes to examine the expression of DNA topoisomerases I and II and chromosome scaffold protein Sc-2 in normal and transformed cells. Neither topoisomerase I nor Sc-2 shows significant fluctuations in content or stability across the cell cycle. In contrast, topoisomerase II undergoes significant cell cycle-dependent alterations in both amount and stability. As cells progress from mitosis into G1, much of the topoisomerase II is degraded. During the first 2 hr of G1, the half life of topoisomerase II is decreased from that measured in asynchronous cell populations by a factor of 7. This suggests that the chromosome condensation/decondensation cycle is coupled to a parallel cycle of synthesis and degradation of topoisomerase II. In control experiments, we also found that the half-life of topoisomerase II is shorter in normal cells than in transformed cells by a factor of 4. Since the number of copies of topoisomerase II per cell is also lower in normal cells, this suggests that control of topoisomerase II stability is altered upon transformation. The stability of topoisomerase I and Sc-2 does not differ significantly between normal and transformed cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2829215      PMCID: PMC279709          DOI: 10.1073/pnas.85.4.1086

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  DNA topoisomerase II is required at the time of mitosis in yeast.

Authors:  C Holm; T Goto; J C Wang; D Botstein
Journal:  Cell       Date:  1985-06       Impact factor: 41.582

Review 2.  DNA topoisomerases.

Authors:  J C Wang
Journal:  Annu Rev Biochem       Date:  1985       Impact factor: 23.643

3.  DNA topoisomerase activities in concanavalin A-stimulated lymphocytes.

Authors:  G Taudou; G Mirambeau; C Lavenot; A der Garabedian; J Vermeersch; M Duguet
Journal:  FEBS Lett       Date:  1984-10-29       Impact factor: 4.124

4.  In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction.

Authors:  M Berrios; N Osheroff; P A Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

5.  Cloning, characterization, and sequence of the yeast DNA topoisomerase I gene.

Authors:  C Thrash; A T Bankier; B G Barrell; R Sternglanz
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

6.  Phosphorylation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro.

Authors:  P Ackerman; C V Glover; N Osheroff
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

7.  Purification and characterization of a type II DNA topoisomerase from bovine calf thymus.

Authors:  B D Halligan; K A Edwards; L F Liu
Journal:  J Biol Chem       Date:  1985-02-25       Impact factor: 5.157

8.  Mitotic spindle pulls but fails to separate chromosomes in type II DNA topoisomerase mutants: uncoordinated mitosis.

Authors:  T Uemura; M Tanagida
Journal:  EMBO J       Date:  1986-05       Impact factor: 11.598

9.  Topoisomerase II is a structural component of mitotic chromosome scaffolds.

Authors:  W C Earnshaw; B Halligan; C A Cooke; M M Heck; L F Liu
Journal:  J Cell Biol       Date:  1985-05       Impact factor: 10.539

10.  Localization of topoisomerase II in mitotic chromosomes.

Authors:  W C Earnshaw; M M Heck
Journal:  J Cell Biol       Date:  1985-05       Impact factor: 10.539

View more
  112 in total

1.  The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53.

Authors:  C Gobert; A Skladanowski; A K Larsen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

2.  Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35.

Authors:  B Grigolo; I Mazzetti; R Meliconi; S Bazzi; R Scorza; M Candela; A Gabrielli; A Facchini
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

3.  Depletion of topoisomerase II in isolated nuclei during a glucose-regulated stress response.

Authors:  J W Shen; J R Subjeck; R B Lock; W E Ross
Journal:  Mol Cell Biol       Date:  1989-08       Impact factor: 4.272

Review 4.  Topoisomerase II: untangling its contribution at the centromere.

Authors:  Andrew C G Porter; Christine J Farr
Journal:  Chromosome Res       Date:  2004       Impact factor: 5.239

5.  Centromeric protein bodies on avian lampbrush chromosomes contain a protein detectable with an antibody against DNA topoisomerase II.

Authors:  Alla Krasikova; Tatiana Kulikova; Alsu Saifitdinova; Svetlana Derjusheva; Elena Gaginskaya
Journal:  Chromosoma       Date:  2004-11-17       Impact factor: 4.316

6.  Topoisomerase II cleavage activity within the human D11Z1 and DXZ1 alpha-satellite arrays.

Authors:  Jennifer M Spence; R E Keith Fournier; Mitsuo Oshimura; Vinciane Regnier; Christine J Farr
Journal:  Chromosome Res       Date:  2005-09-21       Impact factor: 5.239

7.  Protein kinase C delta activates topoisomerase IIalpha to induce apoptotic cell death in response to DNA damage.

Authors:  Kiyotsugu Yoshida; Tomoko Yamaguchi; Hirokuni Shinagawa; Naoe Taira; Keiichi I Nakayama; Yoshio Miki
Journal:  Mol Cell Biol       Date:  2006-05       Impact factor: 4.272

8.  Transcription-induced conformational change in a topologically closed DNA domain.

Authors:  P Dröge; A Nordheim
Journal:  Nucleic Acids Res       Date:  1991-06-11       Impact factor: 16.971

9.  Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis.

Authors:  M G Kauffman; T J Kelly
Journal:  Mol Cell Biol       Date:  1991-05       Impact factor: 4.272

10.  Doxorubicin activity is enhanced by hyperthermia in a model of ex vivo vascular perfusion of human colon carcinoma.

Authors:  Pierluigi Pilati; Simone Mocellin; Carlo R Rossi; Romano Scalerta; Rita Alaggio; Luciano Giacomelli; Cristina Geroni; Donato Nitti; Mario Lise
Journal:  World J Surg       Date:  2003-05-13       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.